Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

摘要: The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). drug binds high affinity 4 5 G-protein-coupled S1P receptors (S1P(1-5)). After binding, are internalized, degraded, and thus functionally antagonized by fingolimod. Under physiologic conditions, S1P(1) mediates egress lymphocytes from secondary lymphoid organs peripheral circulation. Functional antagonism results a reduction lymphocyte counts inhibiting lymphocytes, including potentially encephalitogenic T cells their naive progenitors that would otherwise present within Despite fingolimod-mediated counts, fingolimod-treated MS have few infections related complications were able mount antigen-specific immune responses vaccination studies.